Trials / Completed
CompletedNCT06259383
Oral Ivermectin for Chikungunya Viral Infection
A Randomized Controlled Trial of Oral Ivermectin for Patients With Chikungunya Viral Infection During Urban Outbreak in Southern Thailand
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin | 3-day 1 daily dose of 400 μg/kg oral ivermectin |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2021-12-31
- Completion
- 2024-01-26
- First posted
- 2024-02-14
- Last updated
- 2024-02-14
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT06259383. Inclusion in this directory is not an endorsement.